Aptevo TherapeuticsAPVO
13F holders, Q2 2026 (June 30)9holders
1new positions
0sold out
$4.45avg. 13F price*
At the end of Q2 2026, 9 institutions reported holding Aptevo Therapeutics Inc. (APVO) in their 13F filings, unchanged from Q1 2026. 1 opened new positions and 0 sold out. The largest holders were Gsa Capital Partners LLP ($96K), Vanguard Capital Management LLC ($56K) and Geode Capital Management, LLC ($48K).
- Company
- Aptevo Therapeutics Inc.
- CUSIP
- 03835L702
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $138 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 1,932 shares bought and 5,231 shares sold, net −3,299 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Gsa Capital Partners LLP | 0.01% | Add +9.7% | 21,539 | $96K |
| Vanguard Capital Management LLC | 0.00% | No change | 12,713 | $56K |
| Geode Capital Management, LLC | 0.00% | Reduce -18.9% | 10,821 | $48K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 4,142 | $18K |
| UBS Group AG | 0.00% | Reduce -78.8% | 730 | $3K |
| Osaic Holdings, Inc. | 0.00% | No change | 360 | $2K |
| SBI Securities Co., Ltd. | 0.00% | No change | 109 | $484 |
| Barclays PLC | 0.00% | New | 31 | $138 |
| Danske Bank A/S | 0.00% | No change | 1 | $4 |
"% of holder's portfolio" is APVO's weight in each manager's 13F, not the share of Aptevo Therapeutics Inc. the manager owns.